key: cord-0955315-c3lguqrp
authors: Miller, Lucy; Costelloe, Ceire E.; Robotham, Julie V.; Pouwels, Koen B.
title: Overuse of antibiotics: Can viral vaccinations help stem the tide?
date: 2020-11-30
journal: Br J Clin Pharmacol
DOI: 10.1111/bcp.14651
sha: 1c76fd62e5db64b835efce1688fc068d270a7555
doc_id: 955315
cord_uid: c3lguqrp

nan

Antibiotics have been the cornerstone of modern medicine for the past 80 years and are one of the most common drugs prescribed in healthcare systems worldwide. However, overuse of antibiotics is driving the development and spread of antimicrobial resistance (AMR), compromising the utility of antibiotics to treat and prevent infections. 1 Antibiotic exposure can alter a host's microbiome, thereby increasing the risk of adverse drug events and infections from opportunistic pathogens. 2 If strategies are not implemented to control antibiotic overuse, adverse health and economic impacts are likely, with the burden of AMR disproportionally affecting low and middle-income countries. 1 Within the United Kingdom, there has been a reported 32% rise in the total number of bloodstream infections (BSI) caused by bacteria resistant to one or more key antibiotics from 2014 to 2018. 3 Over 2000 deaths annually are attributable to resistant infections in the United Kingdom. 3 Therefore, to maintain the efficacy of available antibiotics and ensure the continuity of safe and effective healthcare, the U.K. government has continued to push for the optimisation of antibiotic use.

Since 2014, progress in the U.K. has been promising, with an estimated 9% reduction in total healthcare antibiotic prescriptions. 3

The majority of this reduction is a result of a drop in primary care antibiotic prescribing, where approximately three-quarters of total U.K. prescribing takes place. 3,4 Implementation of several antibiotic stewardship interventions, including educational tools, campaigns, and financial incentives, has contributed to the reduction in antibiotic prescribing in primary care. 3

While, for example, lower levels of amoxicillin prescribing in primary care are associated with lower levels of resistance against amoxicillin and trimethoprim among urinary specimens, 5 Reductions are likely a result of strict social isolation measures that have decreased transmission of other communicable diseases in addition to altered health-seeking behaviour in response to the pandemic. Therefore, SARS-CoV-2 may have positive repercussions for both optimal antibiotic prescribing and AMR in primary care.

However, in secondary care, antibiotic treatment is reportedly very high within suspected SARS-CoV-2 patients. 8 Moreover, disruption to immunisation programmes nationally and globally within this pandemic may have substantial repercussions for future infectious disease burden and associated prescribing.

Detailed analysis of primary and secondary care prescribing rates throughout this pandemic will help to understand the impact of SARS-CoV-2. Development of an effective SARS-CoV-2 vaccine that is safe amongst various patient groups will be crucial in alleviating both current and future burden to healthcare and the economy. 11 Interestingly, one recent cost-effective analysis predicted that no national influenza immunisation programme is likely to have a substantial effect on reducing antibiotic consumption and AMR. 12 The above results are not conclusive as the underlying estimates of viral-attributable antibiotic prescribing were dependent on poorly coded RTI's in English primary care. 4 Viral vaccines hold promise as a sustainable alternative for the treatment of infectious disease as viral resistance to vaccines is infrequent. 9 The success of vaccines as an intervention for antibiotic optimisation faces several challenges. Development of vaccines is a difficult process that requires considerable time and financial support. 9 Potential cost-effectiveness of vaccines is likely to be enhanced by accounting for effects on AMR, as most cost-effectiveness models have not yet included impact on antibiotic use and resistance. 9 This is a critical gap as evidence-based cost-effectiveness models will be vital to inform policy decision making and ensuring support for development. Additionally, the uptake of the Measles, mumps, and rubella vaccine 1 (live) for 5-year-olds is consistently below the national 95% coverage target since the first reports in 2013. A recent survey by the Royal Society of Public Health suggests that the most important barriers to getting vaccinated-among those not explicitly anti-vaccination-were timing and availability of appointments and childcare duties. 13 However, with both SARS-CoV-2 and RSV vaccines on the horizon, it will be crucial to better understand the barriers and facilitators of vaccine uptake and how behavioural responses to the pandemic may have changed these. Viral vaccines can alleviate substantial infectious disease burden, support further optimisation of antibiotic prescribing, and potentially help reduce the selection of AMR. The evidence base informing vaccine policy decisions needs to reflect this for true benefits to be realised and support to be maintained. Improvements in the quality of clinical coding throughout healthcare and up to date analysis of prescribing rates within this SARS-CoV-2 pandemic will help to inform more reliable estimates of viral infectious disease burden and associated prescribing within the United Kingdom. These will be vital to inform new viral vaccine cost-effectiveness models that include impact on antibiotic use and AMR. Further research to understand the barriers and facilitators of vaccine uptake will be crucial to achieve the optimal benefits of immunisation programmes. In a time of rising resistant infections, viral vaccinations have the potential to support antibiotic stewardship practice by safely reducing the need for prescribing. However, further studies that also incorporate specific cost-effectiveness models are required to confirm this proposition.

Access to effective antimicrobials: a worldwide challenge

Microbiome as a tool and a target in the effort to address antimicrobial resistance

Potential for reducing inappropriate antibiotic prescribing in English primary care

Selection and co-selection of antibiotic resistances among Escherichia coli by antibiotic use in primary care: an ecological analysis

An ecological comparision of hospital-level antibiotic use and mortality in 36

Why do hospital prescribers continue antibiotics when it is safe to stop? Results of a choice experiment survey

Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study

The Boston Consulting Group. Vaccines to Tackle Drug Resistant Infections An Evaluation of R&D Opportunities

Effectiveness of live attenuated influenza vaccine in preventing amoxicillin prescribing in preschool children: a self-controlled case series study

Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK

Effect of pediatric influenza vaccination on antibiotic resistance, England and Wales

our-work/policy/vaccinations/moving-the-needle-promotingvaccination-uptake-across-the-life-course.html How to cite this article